A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Withdrawn
Study type
Observational
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-16 | estimated | When the study began enrolling |
| Primary completion | 2025-08-16 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-08-16 | estimated | The whole study's end, after follow-up |
| First posted | 2021-05-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-03-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-small Cell Lung Cancer
- Metastatic Colorectal Cancer
- Metastatic Breast Cancer
- Metastatic Kidney Cancer
- Cervical Cancer
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
Intervention
- Drug: Zirabev
Primary outcome
what the primary-completion date above is the date OFSafety profile
measured baseline up to approximately 4 years
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed